X-Chem has announced that it is making changes to its executive management team, with Karen Lackey, the current chief scientific officer (CSO), becoming chief executive officer (CEO) and Matthew Clark, the current CEO pivoting to the role of president and CSO.
Karen brings extensive drug discovery experience in both pharma and service organisations to her new role, in which she will lead the company into the next phase of evolution. The company plans to continue its innovation in data-accelerated drug discovery under her leadership.
In Matthew's new role he will focus on the maintenance of the company’s novel drug discovery technologies, ensuring its clients maintain access to a range of innovative services.
Matthew Clark, X-Chem’s new president and CSO, commented: “I’m very proud of what the team has accomplished over the past four years, transitioning X-Chem from a boutique DNA-encoded library (DEL) shop to a global, integrated service provider. Now, under Karen’s visionary leadership, I am incredibly excited to participate in the next stage of our journey. X-Chem has the potential to transform the way small molecule drugs are discovered.”
Karen Lackey, the company’s incoming CEO, added: “I am so excited about the future of small molecule drug discovery and X-Chem’s role in that future. In my first six months at X-Chem, I have seen top-tier science and met many amazingly talented scientists. Together, we can continue to bring incredible innovation to drug discovery, unlocking the biological problems of the future to the benefit of patients.”
Pharmaceutical Industry news, analysis and insights